Together, these features suggest that combining metabolic intervention (e.g., glycolysis or mitochondrial inhibitors) with immunotherapy may provide synergistic benefits in MLH1-deficient Lynch syndrome-associated colorectal cancer and deserve further pre-clinical and clinical exploration. This evidence concerns the gene MLH1 and Lynch syndrome.